Tag Archives: K-ras

KRAS Mutations Make a Difference In Response to Erbitux

Update from 2008 ASCO Meeting in Chicago Three studies reported during the 2008 American Society of Clinical Oncology found that colorectal cancer patients whose tumors have mutated KRAS genes do not benefit from treatment with the EGFR-inhibitor Erbitux® (cetuximab). At the same time, patients with tumors that aren’t aren’t mutated (wild-type) have significantly better results when Erbitux is added to either FOLFIRI or FOLFOX chemotherapy. Two randomized trials of initial treatment of chemotherapy with or without Erbitux found responses and improved progression-free survival only in patients with wild-type KRAS. The CRYSTAL Phase III study compared FOLFIRI to FOLFIRI with the addition of cetuximab. The Phase II OPUS trial used FOLFOX